Milestone Pharmaceuticals Inc. Common Shares (MIST) is a publicly traded Healthcare sector company. As of May 21, 2026, MIST trades at $1.48 with a market cap of $181.77M and a P/E ratio of -2.00. MIST moved +4.90% today. Year to date, MIST is -25.74%; over the trailing twelve months it is +7.91%. Its 52-week range spans $0.63 to $3.06. Analyst consensus is strong buy with an average price target of $7.25. Rallies surfaces MIST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Milestone Pharmaceuticals Posts $26.1M Q1 Loss, $238K CARDAMYST Revenue: Milestone Pharmaceuticals posted a Q1 net loss of $26.1 million ($0.20 per share), compared with a $20.8 million loss a year earlier, largely driven by higher CARDAMYST launch expenses. Revenue totaled $238,000, and the nascent nasal spray secured 600 prescriptions while the company held $184.2 million in cash.
| Metric | Value |
|---|---|
| Price | $1.48 |
| Market Cap | $181.77M |
| P/E Ratio | -2.00 |
| EPS | $-0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.06 |
| 52-Week Low | $0.63 |
| Volume | 177 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-63.06M |
| Gross Margin | 0.00% |
4 analysts cover MIST: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.25.